Data analysis reveals the staggering extent of patent thicketing in the pharmaceutical industry. AbbVie filed 247 patents on Humira alone—generating over 200 billion dollars in sales through artificial monopolies rather than therapeutic innovation. This single case demonstrates how regulatory systems enable companies to maintain market exclusivity through litigation barriers that make generic drug entry financially prohibitive.
The practice extends across the industry: Gilead filed 161 patents on HIV medications, while Bristol Myers and Merck pursued similar strategies. These patent clusters serve no public health purpose; instead, they create legal mazes that delay generic competition and inflate medication costs for healthcare systems worldwide. Patent offices continue approving applications for trivial modifications—from changing pill frequency to minor formulation adjustments—that provide minimal clinical benefit. This systematic abuse of intellectual property protections undermines healthcare equity and demands urgent regulatory reform.
Read the full article on GMJ Newsroom.
Was this article helpful?
